Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapies

This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.

Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

NHS England’s commissioning expert told NICE that healthcare professionals would require “extensive training in managing and supporting patients”who had received CAR-T therapies, and that a new service specification ... NICE's Meindert Boysen.

Latest news

More from news
Approximately 3 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... The challenges ahead are to improve the

  • The good, the bad and the ugly The good, the bad and the ugly

    The company hopes its $12bn acquisition of Kite Pharma (August 2017) will help it steal a march on the lucrative CAR-T market through its treatment for advanced lymphoma. ... It will also be interesting to see how gene therapies and cell-based therapies,

  • Cell and gene therapies: on course for commercial success? Cell and gene therapies: on course for commercial success?

    The data for the research was derived from published data on CAR-T pipeline therapies, but was not related to any particular product. ... transplant. As a result, there may be no existing mechanism for these centres to obtain funding for any additional,

  • Deal Watch November 2016 Deal Watch November 2016

    were thought to be a result of the chemotherapy regimen used to prepare the patients before administering the CAR T cell therapy. ... their own CAR T cell therapies - so CAR T cell therapy seems to be still alive and doing well.

  • Deal Watch September 2016 Deal Watch September 2016

    The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... 800. Arrowhead / Amgen. Licences. 2 agreements to develop and

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... From dream to reality. The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to reality,

  • Addressing the biggest challenges for rare disease communities

    It is common that primary care physicians either do not recognise specific symptoms or don’ t make the link between common symptoms and a rare disease. ... And just last year, we saw landmark breakthroughs in advanced genetic therapies, such as viral

  • Addressing the biggest challenges for rare disease communities

    It is common that primary care physicians either do not recognise specific symptoms or don’ t make the link between common symptoms and a rare disease. ... And just last year, we saw landmark breakthroughs in advanced genetic therapies, such as viral

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics